Sulforaphane-induced epigenetic regulation of Nrf2 expression by DNA methyltransferase in human Caco-2 cells.
Level 5 - mechanism / opinion, no new human data
In vitro laboratory study in human cell lines without clinical or in vivo human data.
PubMed 31452747 · doi:10.3892/ol.2019.10569
What was done
Human Caco-2 colon cells were treated with sulforaphane, a combination of 5-aza-2'-deoxycytidine (5-Aza) and trichostatin A (TSA), or control conditions. Researchers assessed DNA methyltransferase 1 (DNMT1) mRNA, protein levels, and activity. They evaluated CpG methylation in the Nrf2 promoter region using methylation-specific PCR and bisulfite genomic sequencing, and measured Nrf2 mRNA and protein levels via RT-qPCR and western blot analysis.
What was found
The abstract reports no numerical values, effect sizes, or confidence intervals. Sulforaphane did not alter DNMT1 mRNA expression, but it inhibited DNMT1 protein expression, as did 5-Aza + TSA. Nrf2 promoter methylation decreased significantly following sulforaphane treatment relative to controls, with 5-Aza + TSA showing the lowest methylation levels. Nrf2 mRNA levels differed significantly between sulforaphane, 5-Aza + TSA, and control groups. Nrf2 protein expression was reported as inhibited by both sulforaphane and 5-Aza + TSA co-treatment.
Why it matters
This study provides mechanistic evidence that sulforaphane can modulate DNA methyltransferase activity and induce demethylation of the Nrf2 promoter in cultured colon cancer cells.
Limits
This is an in vitro cell culture study in a single immortalized cell line (Caco-2), providing no direct evidence of in vivo efficacy, bioavailability, or clinical cancer prevention in humans. The abstract omits quantitative data, dose concentrations, exposure times, and replicate numbers.
Cited by
- supports Sulforaphane treatment upregulates RNA expression levels of Nrf2 and Keap1.